Teleflex Incorporated (TFX) has been garnering attention in the recent news period for a variety of reasons. Analysts expect a
decline in earnings from the company. The company has also announced its Q2 2025 results and a
second quarter earnings conference call. Fraud investigations linked to the company have given investors an opportunity to join. The company has also declared
an upcoming US$0.34 dividend. The
spin-off announcements have adversely influenced the company's stock which fell as a result. Teleflex recently completed its
acquisition of BIOTRONIK's Vascular Intervention Business. Financials of the company appear mixed, driving negative sentiment. The company also announced its intent to separate into two publicly traded companies. Teleflex recently faced a downgrade at Bank of America. Despite hitting a 52-week low multiple times amid market challenges, the medical instrument supplier has reported first quarter financial results and initiated a
$300 million accelerated share buyback. A class action
securities fraud investigation has been started on behalf of Teleflex investors. There have been layoffs in Minnesota. They has also launched UroLift 2 and completed the acquisition of Palette Life Sciences.
Teleflex Incorporated TFX News Analytics from Fri, 21 Jul 2017 05:48:50 GMT to Thu, 24 Jul 2025 18:43:49 GMT -
Rating 0
- Innovation -5
- Information 6
- Rumor -4
